نتایج جستجو برای: everolimus

تعداد نتایج: 3889  

2014
Martine Dubois Vadim Le Joncour Marie-Christine Tonon Youssef Anouar François Proust Fabrice Morin Pierrick Gandolfo Florence Joly Pascal Hilber Hélène Castel

Cancer and treatments may induce cognitive impairments in cancer patients, and the causal link between chemotherapy and cognitive dysfunctions was recently validated in animal models. New cancer targeted therapies have become widely used, and their impact on brain functions and quality of life needs to be explored. We evaluated the impact of everolimus, an anticancer agent targeting the mTOR pa...

2017
Cristian Lolli Valentina Gallà Giuseppe Schepisi Domenico Barone Salvatore Luca Burgio Antonio Maugeri Bernadette Vertogen Dino Amadori Ugo De Giorgi

LESSONS LEARNED The combination of everolimus and low-dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all-grade NIP occurred in four of eight cases (50%), and this was considered enough to stop accrual of the study.These data suggest th...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2014
M Aapro F Andre K Blackwell E Calvo M Jahanzeb K Papazisis C Porta K Pritchard A Ravaud

BACKGROUND Everolimus, an orally administered rapamycin analogue, inhibits the mammalian target of rapamycin (mTOR), a highly conserved intracellular serine-threonine kinase that is a central node in a network of signaling pathways controlling cellular metabolism, growth, survival, proliferation, angiogenesis, and immune function. Everolimus has demonstrated substantial clinical benefit in rand...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016
James C Yao Marianne Pavel Catherine Lombard-Bohas Eric Van Cutsem Maurizio Voi Ulrike Brandt Wei He David Chen Jaume Capdevila Elisabeth G E de Vries Paola Tomassetti Timothy Hobday Rodney Pommier Kjell Öberg

Purpose Everolimus improved median progression-free survival by 6.4 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the RADIANT-3 study. Here, we present the final overall survival (OS) data and data on the impact of biomarkers on OS from the RADIANT-3 study. Methods Patients with advanced, progressive, low- or intermediate-grade pancreatic NET w...

2015
T. C. Schneider D. de Wit T. P. Links N. P. van Erp J. J. M. van der Hoeven H. Gelderblom T. van Wezel R. van Eijk H. Morreau H. J. Guchelaar E. Kapiteijn

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MTC. Methods. Seven patients with per RECIST 1.1 documented advanced MTC were included and received...

2016
Lin Liu Zhi-Hui Wang Jun Han Con Tang Nan Chen Zhong Lin Pei-Jian Peng

BACKGROUND Nasopharyngeal carcinoma (NPC) has a high relapse and metastatic rates; hence, development of new therapeutics is an immediate requirement. Lapatinib and everolimus have been demonstrated to be effective in the treatment of several carcinomas. This preclinical study aimed to investigate the effect and mechanism of lapatinib combined with everolimus on NPC cells. METHODS The Cell Co...

2017
Jan Van Keer David Derthoo Olivier Van Caenegem Michel De Pauw Eric Nellessen Nathalie Duerinckx Walter Droogne Gábor Vörös Bart Meyns Ann Belmans Stefan Janssens Johan Van Cleemput Johan Vanhaecke

In this 3-year, open-label, multicenter study, 57 maintenance heart transplant recipients (>1 year after transplant) with renal insufficiency (eGFR 30-60 mL/min/1.73 m2) were randomized to start everolimus with CNI withdrawal (N = 29) or continue their current CNI-based immunosuppression (N = 28). The primary endpoint, change in measured glomerular filtration rate (mGFR) from baseline to year 3...

2012
A Faggiano V Ramundo A Dicitore S Castiglioni M O Borghi R Severino P Ferolla L Crinò A Abbruzzese P Sperlongano M Caraglia D Ferone L Hofland A Colao G Vitale

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calcitonin...

Journal: :Revista de Medicina da Universidade Federal do Ceará 2023

Objetivo: Relatar o caso de uma paciente que desenvolveu pneumonia em organização (PO) com presumida associação ao uso do everolimus. Metodologia: Estudo tipo relato caso, tendo os dados sido coletados por meio prontuário médico e a revisão bibliográfica pesquisada pelo PUBMED. Resultados: O é 66 anos realizou transplante renal, após, iniciou tacrolimus Depois 1 ano cinco meses tosse seca febre...

Journal: :Neurology 2016
Darcy A Krueger Angus A Wilfong Maxwell Mays Christina M Talley Karen Agricola Cindy Tudor Jamie Capal Katherine Holland-Bouley David Neal Franz

OBJECTIVE To evaluate the long-term benefit and safety of everolimus for the treatment of medically refractory epilepsy in patients with tuberous sclerosis complex (TSC). METHODS Everolimus was titrated over 4 weeks and continued an additional 8 weeks in a prospective, open-label, phase I/II clinical trial design. Participants demonstrating initial benefit continued treatment until study comp...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید